[go: up one dir, main page]

CL2007003395A1 - USE OF AGOMELATIN FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF PERIVENTRICULAR LEUCOMALACY. - Google Patents

USE OF AGOMELATIN FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF PERIVENTRICULAR LEUCOMALACY.

Info

Publication number
CL2007003395A1
CL2007003395A1 CL200703395A CL2007003395A CL2007003395A1 CL 2007003395 A1 CL2007003395 A1 CL 2007003395A1 CL 200703395 A CL200703395 A CL 200703395A CL 2007003395 A CL2007003395 A CL 2007003395A CL 2007003395 A1 CL2007003395 A1 CL 2007003395A1
Authority
CL
Chile
Prior art keywords
leucomalacy
agomelatin
periventricular
obtaining
treatment
Prior art date
Application number
CL200703395A
Other languages
Spanish (es)
Inventor
Spedding Elisabeth Moc Michael
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003395(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2007003395A1 publication Critical patent/CL2007003395A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200703395A 2006-11-24 2007-11-22 USE OF AGOMELATIN FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF PERIVENTRICULAR LEUCOMALACY. CL2007003395A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610294A FR2908994B1 (en) 2006-11-24 2006-11-24 USE OF AGOMELATIN FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF PERIVENTRICULAR LEUKOMALACY

Publications (1)

Publication Number Publication Date
CL2007003395A1 true CL2007003395A1 (en) 2008-09-12

Family

ID=38229589

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703395A CL2007003395A1 (en) 2006-11-24 2007-11-22 USE OF AGOMELATIN FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF PERIVENTRICULAR LEUCOMALACY.

Country Status (37)

Country Link
US (1) US20080125493A1 (en)
EP (1) EP1927351B1 (en)
JP (1) JP4870062B2 (en)
KR (1) KR100976000B1 (en)
CN (1) CN101185644B (en)
AR (1) AR063895A1 (en)
AT (1) ATE483458T1 (en)
AU (1) AU2007234600B2 (en)
BR (1) BRPI0704179A (en)
CA (1) CA2610637C (en)
CL (1) CL2007003395A1 (en)
CY (1) CY1110875T1 (en)
DE (1) DE602007009627D1 (en)
DK (1) DK1927351T3 (en)
EA (1) EA014067B1 (en)
ES (1) ES2353128T3 (en)
FR (1) FR2908994B1 (en)
GE (1) GEP20094747B (en)
HR (1) HRP20100680T1 (en)
JO (1) JO2631B1 (en)
MA (1) MA29522B1 (en)
ME (1) ME01866B (en)
MX (1) MX2007014004A (en)
MY (1) MY145925A (en)
NO (1) NO338598B1 (en)
NZ (1) NZ563683A (en)
PE (1) PE20081158A1 (en)
PL (1) PL1927351T3 (en)
PT (1) PT1927351E (en)
RS (1) RS51494B (en)
SG (1) SG143202A1 (en)
SI (1) SI1927351T1 (en)
TW (1) TW200829236A (en)
UA (1) UA94043C2 (en)
UY (1) UY30703A1 (en)
WO (1) WO2008071869A2 (en)
ZA (1) ZA200710102B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2810656T3 (en) 2013-06-06 2018-01-31 Zentiva Ks Agomelatine formulations comprising agomelatine in the form of co-crystals
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (en) * 1990-02-27 1993-12-31 Adir Cie NOVEL DERIVATIVES WITH NAPHTHALENIC STRUCTURE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6921775B2 (en) * 2001-08-03 2005-07-26 Children's Medical Center Corporation Methods for modulating brain damage
FR2866335B1 (en) * 2004-02-13 2006-05-26 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
CY1110875T1 (en) 2015-06-10
FR2908994A1 (en) 2008-05-30
PT1927351E (en) 2010-10-27
RS51494B (en) 2011-04-30
ZA200710102B (en) 2008-11-26
GEP20094747B (en) 2009-07-27
EP1927351A1 (en) 2008-06-04
EA200702317A1 (en) 2008-06-30
NO20076002L (en) 2008-05-26
FR2908994B1 (en) 2009-04-03
HRP20100680T1 (en) 2011-01-31
CN101185644B (en) 2011-08-10
NZ563683A (en) 2009-04-30
ATE483458T1 (en) 2010-10-15
DE602007009627D1 (en) 2010-11-18
ES2353128T3 (en) 2011-02-25
PL1927351T3 (en) 2011-01-31
EP1927351B1 (en) 2010-10-06
SG143202A1 (en) 2008-06-27
AU2007234600A1 (en) 2008-06-12
KR100976000B1 (en) 2010-08-17
DK1927351T3 (en) 2011-01-10
EA014067B1 (en) 2010-08-30
UY30703A1 (en) 2008-01-02
JP4870062B2 (en) 2012-02-08
CA2610637C (en) 2011-04-19
MX2007014004A (en) 2009-02-16
CN101185644A (en) 2008-05-28
TW200829236A (en) 2008-07-16
AU2007234600A8 (en) 2010-12-02
US20080125493A1 (en) 2008-05-29
MY145925A (en) 2012-05-15
WO2008071869A2 (en) 2008-06-19
NO338598B1 (en) 2016-09-12
JO2631B1 (en) 2012-06-17
AU2007234600B2 (en) 2012-05-17
MA29522B1 (en) 2008-06-02
ME01866B (en) 2011-04-30
SI1927351T1 (en) 2010-12-31
JP2008133279A (en) 2008-06-12
HK1118216A1 (en) 2009-02-06
KR20080047298A (en) 2008-05-28
UA94043C2 (en) 2011-04-11
CA2610637A1 (en) 2008-05-24
WO2008071869A3 (en) 2008-08-14
AR063895A1 (en) 2009-02-25
PE20081158A1 (en) 2008-10-04
BRPI0704179A (en) 2008-07-08

Similar Documents

Publication Publication Date Title
HUS1600048I1 (en) Preparation for the treatment of Fabry disease
BRPI0811635A2 (en) ARILAZOL-2-IL CYANOETHYLAMINE COMPOUNDS, METHODS FOR MAKING THEM AND METHODS FOR THE USE OF THEM
BRPI0716844A2 (en) Useful Kinase Inactors for the Treatment of Proliferative Diseases
CL2007002974A1 (en) COMPOUNDS DERIVED FROM BENZOIMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DGAT1.
CL2007001040A1 (en) PROCESS FOR THE PREPARATION OF ANTAGONIST OF THE SUBSTANCE P DERIVED FROM ACIL-AMINO-ALQUILEN-AMIDA.
BRPI0816784A2 (en) Neuroendocrine factors for the treatment of degenerative diseases
BRPI1012993A2 (en) "Use of an anti-tau ps422 antibody for the treatment of brain disease"
DK1928438T3 (en) Use of ibudilast for the treatment of drug dependence
BRPI0816881A2 (en) Compound, pharmaceutical composition, use of a compound, and methods for treating diseases or disorders and for preparing a compound.
CL2007002837A1 (en) USE OF PHENITOIN TO TREAT ORAL MUCOSITIS.
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
BRPI0818459A2 (en) Pharmaceutical composition suitable for ophthalmic use.
BRPI0911577A8 (en) spiroindole derivatives for the treatment of parasitic diseases.
BRPI0912539A2 (en) compound, pharmaceutical composition, method for treating a disease, and use of the compound.
CL2007001630A1 (en) COMPOUNDS DERIVED FROM PIRROLIDINAMIDE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF HEPATITIS C.
BRPI0818170A2 (en) 5-cyanothienopyridines for the treatment of tumors.
BRPI0912687A2 (en) use of probiotic bacteria for the treatment of hyperhomocysteinemia
BRPI0720323A2 (en) compound, method of treatment, pharmaceutical composition and use of the compound
BRPI0911772A2 (en) compound, pharmaceutical composition, and use of the compound.
PT2056805E (en) USE OF 2.5-DI-HYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTION
BRPI0919694A2 (en) compound, pharmaceutical compound, use of a compound, and method of treating a disease.
BRPI0907956A2 (en) Use of ranolazine for the treatment of cardiovascular disease
BRPI0911515A2 (en) rotary forming devices and methods for the use of such devices.
BR112012002311A2 (en) compound, pharmaceutical composition, and use of the compound.
CL2007003395A1 (en) USE OF AGOMELATIN FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF PERIVENTRICULAR LEUCOMALACY.